Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

被引：137
|
作者：
Soverini, Simona [1 ]
Branford, Susan [2 ,3 ,4 ]
Nicolini, Franck E. [1 ,5 ]
Talpaz, Moshe
Deininger, Michael W. N. [6 ]
Martinelli, Giovanni [1 ]
Mueller, Martin C. [7 ]
Radich, Jerald P. [8 ]
Shah, Neil P. [9 ]
机构：
[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] SA Pathol, Dept Mol Pathol, Ctr Canc Biol, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia
[5] Ctr Hosp Lyon Sud, Hematol Dept 1G, F-69310 Pierre Benite, France
[6] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[7] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[9] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期
关键词：
BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations; DIAGNOSED CHRONIC-PHASE; BCR-ABL MUTATIONS; DASATINIB; 100; MG; PHILADELPHIA-POSITIVE PATIENTS; GIMEMA WORKING PARTY; IMATINIB-RESISTANT; FOLLOW-UP; HIGH-RISK; CML; CHROMOSOME;
D O I：
10.1016/j.leukres.2013.09.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：10 / 20
页数：11
相关论文
共 50 条
  • [41] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
    Takeuchi, Asako
    Kondo, Toshinori
    Tasaka, Taizo
    Yamada, Seiko
    Hirose, Tadashi
    Fukuda, Hirofumi
    Shimizu, Risa
    Matsuhashi, Yoshiko
    Kondo, Eisei
    Wada, Hideho
    LEUKEMIA RESEARCH REPORTS, 2021, 15
  • [42] Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
    Soverini, Simona
    Abruzzese, Elisabetta
    Bocchia, Monica
    Bonifacio, Massimiliano
    Galimberti, Sara
    Gozzini, Antonella
    Iurlo, Alessandra
    Luciano, Luigiana
    Pregno, Patrizia
    Rosti, Gianantonio
    Saglio, Giuseppe
    Stagno, Fabio
    Tiribelli, Mario
    Vigneri, Paolo
    Barosi, Giovanni
    Breccia, Massimo
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [43] EARLY PREDICTION OF THE MOLECULAR RESPONSE TO BCR-ABL1 TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
    Noh, H.
    Choi, S. -Y.
    Song, H. -Y.
    Kim, S. -H.
    Jung, S. Y.
    Yang, S.
    Lee, W. -S.
    Kim, H. -J.
    Kong, J. H.
    Kim, H.
    Do, Y. R.
    Kwak, J. -Y.
    Oh, S.
    Kim, S. H.
    Kim, J. -A.
    Zang, D. Y.
    Mun, Y. -C.
    Won, Y. -W.
    Lee, S. -E.
    Kim, D. -W.
    Lee, J.
    HAEMATOLOGICA, 2017, 102 : 76 - 76
  • [44] BCR- ABL KINASE MUTATIONS TO IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Thungappa, S. Chiradoni
    Singh, T.
    Rashmi, N. R.
    Lokanatha, D.
    Rajshekar, H.
    Lakshmaiah, K. C.
    Babu, K. G.
    Suresh, T. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 357 - 357
  • [45] Molecular Monitoring of Chronic Myeloid Leukemia International Standardization of BCR-ABL1 Quantitation
    Zhen, ChaoJie
    Wang, Y. Lynn
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (05): : 556 - 564
  • [46] Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient
    Zamecnikova, Adriana
    Al Bahar, Soad
    Pandita, Ramesh
    HEMATOLOGY, 2012, 17 (06) : 321 - 324
  • [47] Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia
    Langabeer, Stephen E.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (08) : 969 - 969
  • [48] Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
    Smith, Brittany M.
    Brewer, Diana
    Druker, Brian J.
    Braun, Theodore P.
    CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1707 - 1711
  • [49] Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia
    Tang, Yanjing
    Wei, Xiaoyuan
    Chen, Jing
    Du, Yunzhi
    Chu, Huiling
    Mao, Louise
    Chen, Jun
    Xu, Qing
    Tang, Jingyan
    Shen, Shuhong
    Mao, Mao
    LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2216 - 2218
  • [50] BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia
    Srutova, Klara
    Curik, Nikola
    Burda, Pavel
    Savvulidi, Filipp
    Silvestri, Giovannino
    Trotta, Rossana
    Klamova, Hana
    Pecherkova, Pavla
    Sovova, Zofie
    Koblihova, Jitka
    Stopka, Tomas
    Perrotti, Danilo
    Polakova, Katerina Machova
    HAEMATOLOGICA, 2018, 103 (12) : 2016 - 2025
12345